Nurver Akıncı

Nurver Akıncı

Auto-generated profile, based on publicly available information

Nurver Akıncı

Department of Pediatric Nephrology, Bezmialem Vakif University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Urology Research and Practice
Verified
Journal Article
Closed access
NANurver Akıncı
Nurver Akıncı
AÇAdviye Çakıl
Adviye Çakıl
AÖAyşe Öner
Ayşe Öner
Xanthine dehydrogenase catalyzes the oxidation of hypoxanthine to xanthine and xanthine to uric acid in the final two steps of purine degradation. Xanthine oxidase deficiency is an uncommon cause of pediatric urinary stone formation and classical xanthinuria. A ten-month-old boy presented with a seven-month history of nausea, vomiting, discomfort during urination, gross hematuria and passage of stones. His renal and liver function tests and electrolytes were normal, but serum and urine uric acid were undetectable. Ultrasonographic evaluation of the urinary tract revealed the presence of multiple bilateral renal stones. The renal stones were analyzed using an X-ray diffractometer and were found to be composed of hypoxanthine-xanthine. High fluid intake, alkalinization and a low-purine diet were prescribed, and extracorporeal shock wave lithotripsy was performed. Recurrent renal stone formation was not observed during 18 months of follow-up. This case is reported to highlight the nature of this rare condition.

1 November 2021 in Cell Stress and Chaperones
Verified
Journal Article
Open access
PDF file
ZYZeynep Nagehan Yuruk Yildirim
Zeynep Nagehan Yuruk Yildirim
SASEBAHAT USTA AKGUL
SEBAHAT USTA AKGUL
HAHarika Alpay
Harika Alpay
BABagdagul Aksu
Bagdagul Aksu
FOFatma Savran Oguz
Fatma Savran Oguz
AYAlev Yilmaz
Alev Yilmaz
Various molecular and cellular processes are involved in renal fibrosis, such as oxidative stress, inflammation, endothelial cell injury, and apoptosis. Heat shock proteins (HSPs) are implicated in the progression of chronic kidney disease (CKD). Our aim was to evaluate changes in urine and serum HSP levels over time and their relationships with the clinical parameters of CKD in children. In total, 117 children with CKD and 56 healthy children were examined. The CKD group was followed up prospectively for 24 months. Serum and urine HSP27, HSP40, HSP47, HSP60, HSP70, HSP72, and HSP90 levels and serum anti-HSP60 and anti-HSP70 levels were measured by ELISA at baseline, 12 months, and 24 months. The urine levels of all HSPs and the serum levels of HSP40, HSP47, HSP60, HSP70, anti-HSP60, and anti-HSP70 were higher at baseline in the CKD group than in the control group. Over the months, serum HSP47 and HSP60 levels steadily decreased, whereas HSP90 and anti-HSP60 levels steadily increased. Urine HSP levels were elevated in children with CKD; however, with the exception of HSP90, they decreased over time. In conclusion, our study demonstrates that CKD progression is a complicated process that involves HSPs, but they do not predict CKD progression. The protective role of HSPs against CKD may weaken over time, and HSP90 may have a detrimental effect on the disease course.

7 April 2020 in Journal of Pediatric Intensive Care
Verified
Journal Article
Closed access
PDF file
OYOsman Yesilbas
Osman Yesilbas
CYCan Yilmaz Yozgat
Can Yilmaz Yozgat
NANurver Akinci
Nurver Akinci
FTFaraz Talebazadeh
Faraz Talebazadeh
UJUzeyir Jafarov
Uzeyir Jafarov
YYYilmaz Yozgat
Yilmaz Yozgat
Gastrointestinal, neurological, pancreatic, hepatic, and cardiac dysfunction are extrarenal manifestations of hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC-HUS). The most frequent cause of death for STEC-HUS is related to the central nervous system and cardiovascular system. Cardiac-origin deaths are predominantly related to thrombotic microangiopathy-induced ischemia and the immediate development of circulatory collapse. STEC-HUS cardiac related deaths in children are rare with only sporadic cases reported. In our literature search, we did not come across any pediatric case report about STEC-HUS causing sudden cardiac arrest and malignant ventricular tachycardia (VT). Herein, we report the case of an 8-year-old female child with a typical clinical manifestation of STEC-HUS. On the seventh day of pediatric intensive care unit admission, the patient had a sudden cardiac arrest, requiring resuscitation for 10 minutes. The patient had return of spontaneous circulation with severe monomorphic pulsed malignant VT. Intravenous treatment with lidocaine, amiodarone and magnesium sulfate were promptly initiated, and we administered multiple synchronized cardioversions, but VT persisted. Furthermore, we were not able to ameliorate her refractory circulation insufficiency by advanced cardiopulmonary resuscitation. Thus, inevitably, the patient lost her life. This case illustrates the need for aggressive management and the dilemma that pediatric critical care specialists, cardiologists, and nephrologists have to face when dealing with STEC-HUS that is worsened by a sudden cardiac arrest accompanied with VT.

30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
MTMehmet Taşdemir
Mehmet Taşdemir
NCNur Canpolat
Nur Canpolat
NYNurdan Yildiz
Nurdan Yildiz
GÖGül Özçelik
Gül Özçelik
MBMeryem Benzer
Meryem Benzer
IBIlmay Bilge
Ilmay Bilge
Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen. Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m(2)) or high (2-4 doses of 375 mg/m(2)) initial dose of rituximab and the steroid response. Clinical outcomes were compared. Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9-17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 +/- 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups. Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.

5 August 2020 in Journal of Pediatric Intensive Care
Verified
Journal Article
Closed access
PDF file
OYOsman Yesilbas
Osman Yesilbas
CYCan Yilmaz Yozgat
Can Yilmaz Yozgat
NANurver Akinci
Nurver Akinci
SSSirin Sonmez
Sirin Sonmez
ETEser Tekin
Eser Tekin
YYYilmaz Yozgat
Yilmaz Yozgat
Cardiovascular involvement is uncommon in pediatric patients with hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC-HUS). In this case report we presented a case of 17-month-old toddler who had a sporadic type of STEC-HUS complicated by acute myocarditis. The patient was successfully treated by a single dose of eculizumab after six doses of therapeutic plasma exchange (TPE) were inefficient to prevent the cardiac complication. Hepatotoxicity was observed after a single dose of eculizumab. Hepatic and cholestatic enzyme levels slowly returned to normal within 6 months. To the best of our knowledge, this is the first case of myocarditis/cardiomyopathy treated with eculizumab in STEC-HUS. This case illustrates the need for vigilance regarding myocardial involvement and eculizumab-induced hepatotoxicity in STEC-HUS.

16 January 2022 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
EYEsra Karabağ Yılmaz
Esra Karabağ Yılmaz
SSSeha Kamil Saygili
Seha Kamil Saygili
BGBora Gulhan
Bora Gulhan
NCNur Canpolat
Nur Canpolat
ABAysun Karabay Bayazıt
Aysun Karabay Bayazıt
FOFatih Ozaltin
Fatih Ozaltin